Condition
HER2 Low Breast Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 6 HER2 Low Breast Carcinoma clinical trials that are recruiting, at sites in 3 countries (most in United States (3), China (2), France (1)). By phase: Phase 1/2 (3), Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 3Countries
Newest HER2 Low Breast Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer | Phase 2 | Guangzhou, Guangdong | Recruiting | Sep 1, 2026 |
| Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy | Phase 1/2 | Boston, Massachusetts | Recruiting | Sep 30, 2025 |
| Exploring HER3-DXd treatment for advanced breast cancer | Phase 1/2 | Villejuif, France | Recruiting | Mar 7, 2024 |
| ARX788 for HER2-low breast cancer | Phase 2 | San Francisco, California | Recruiting | Jan 25, 2024 |
| Neoadjuvant treatment for HR-positive, low HER2 breast cancer | Phase 2 | Zhengzhou, Henan | Recruiting | Jun 22, 2023 |
| Platform program for evaluating treatments in metastatic HER2-positive breast cancer | Phase 1/2 | Birmingham, Alabama and 9 other locations | Recruiting | May 22, 2023 |
All recruiting trials (6)
-
Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer
This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.
-
Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy
This trial tests whether combining elacestrant with trastuzumab deruxtecan helps people with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after CDK4/6 inhibitor and endocrine treatment.
-
Exploring HER3-DXd treatment for advanced breast cancer
This study is testing a new treatment called HER3-DXd, both alone and with another drug, to see if it can help people with advanced breast cancer that hasn't responded to previous treatments.
-
ARX788 for HER2-low breast cancer
This phase 2 study tests ARX788 as a single-drug treatment for adults with HER2-low locally advanced unresectable or metastatic breast cancer.
-
Neoadjuvant treatment for HR-positive, low HER2 breast cancer
This study is testing a new treatment called SHR-A1811 to see if it can help people with early-stage HR-positive, low HER2 breast cancer before they have surgery.
-
Platform program for evaluating treatments in metastatic HER2-positive breast cancer
This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.
Related topics
Quick answers
How many HER2 Low Breast Carcinoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (3 trials), China (2 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.